{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"ORR: percentage of participants who achieve complete response (CR) or partial response (PR) or better per investigator assessment by IMWG.CR: Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \\<5 percent (%) plasma cells in bone marrow (BM). PR: \\>50 percent (%) reduction of serum M-protein and reduction in 24 hours (h) urinary M-protein by \\>90% or to less than (\\<) 200 milligrams per 24 hour (mg/24 h); If serum and urine M-protein were unmeasurable, \\>50% decrease in difference between involved and uninvolved free light chain (FLC) levels was required in place of M-protein criteria; If serum and urine M-protein are not measurable, and serum free light assay was also not measurable, \\>50% reduction in plasma cells is required in place of M-protein, provided baseline BM plasma cell percentage was \\>30%. In addition to the above listed criteria, if present at baseline, a \\>50% reduction in the size of soft tissue plasmacytomas is also required.","groups":[{"description":"Participants were planned to receive TAK-981 recommended phase 2 dose (RP2D), infusion, intravenously, in combination with an anti-CD38 antibody (mezagitamab or daratumumab and hyaluronidase-fihj), injection, subcutaneously, for up to 24 cycles or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG000","title":"Phase 2: TAK-981 (RP2D) + Selected Anti-CD38 Antibody"}],"populationDescription":"The study was terminated after completion of Phase 1b Part 1, therefore, no participants were enrolled in Phase 2 part of the study. Hence, the data for this outcome measure could not collected, analyzed and reported.","reportingStatus":"POSTED","timeFrame":"From date of treatment start to until date of first PD or death (whichever occurred first), up to 24 months","title":"Phase 2: Overall Response Rate (ORR)","type":"PRIMARY"}